Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy
Authors:
- 1 November 2018
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 25 (13) , 1746-1753
Abstract
Background: The rate of post-relapse residual disability in patients with relapsing–remitting multiple sclerosis (RRMS) treated with disease-modifying drugs (DMD) has not been studied. Objective: To assess relapse residual disability in DMD-treated RRMS patients. Methods: We followed DMD-treated RRMS patients presenting with acute relapse who received high-dose steroids. Increases in Expanded Disability Status Scale (EDSS) of at least 2.0, 1.0–1.5 or 0.5 were defined as severe, moderate or mild relapses, respectively. The proportions of patients with post-relapse residual disability defined as the failure to regain pre-relapse neurological status at 1, 4 and 12 months were evaluated. Results: Out of 1672 relapses in DMD-treated RRMS patients, 17% were severe. In patients who presented with a severe relapse, we observed post-relapse residual disability of at least 1.0 EDSS point in 60.1%, 55.9% and 48.2% of patients at 1, 2 and 12 months of follow-up, respectively. Post-relapse residual disability of at least 2.0 EDSS points was observed in 37.4%, 30.7% and 20.7% of patients after 1, 2 and 12 months, respectively. Conclusion: A high rate of incomplete recovery was seen 12 months following severe relapse among RRMS patients and may contribute to the accumulation of long-term disability.Keywords
This publication has 17 references indexed in Scilit:
- Poor early relapse recovery affects onset of progressive disease course in multiple sclerosisNeurology, 2015
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatmentClinical Neurology and Neurosurgery, 2006
- Axonal Transection in the Lesions of Multiple SclerosisNew England Journal of Medicine, 1998
- A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic NeuritisNew England Journal of Medicine, 1992
- A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.Journal of Neurology, Neurosurgery & Psychiatry, 1987
- High‐dose intravenous methylprednisolone in the treatment of multiple sclerosisNeurology, 1986
- Rating neurologic impairment in multiple sclerosisNeurology, 1983
- COURSE AND PROGNOSIS OF MULTIPLE SCLEROSIS ASSESSED BY THE COMPUTERIZED DATA PROCESSING OF 349 PATIENTSBrain, 1980
- Multiple sclerosis: a review.BMJ, 1973